Weiss Asset Management LP Makes New $1.76 Million Investment in Cibus, Inc. $CBUS

Weiss Asset Management LP acquired a new stake in Cibus, Inc. (NASDAQ:CBUS) in the first quarter, Holdings Channel reports. The fund acquired 888,124 shares of the company’s stock, valued at approximately $1,758,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. OMERS ADMINISTRATION Corp bought a new position in shares of Cibus during the first quarter worth approximately $66,000. Renaissance Technologies LLC raised its position in shares of Cibus by 42.5% in the first quarter. Renaissance Technologies LLC now owns 98,900 shares of the company’s stock valued at $196,000 after buying an additional 29,500 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in shares of Cibus in the first quarter valued at approximately $33,000. Corient Private Wealth LLC bought a new stake in shares of Cibus in the fourth quarter valued at approximately $145,000. Finally, PACK Private Wealth LLC acquired a new stake in Cibus during the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

Cibus Price Performance

CBUS stock opened at $1.70 on Monday. Cibus, Inc. has a 12 month low of $1.09 and a 12 month high of $4.19. The firm has a market cap of $129.76 million, a P/E ratio of -0.86 and a beta of 1.65. The company’s 50-day moving average price is $1.50 and its two-hundred day moving average price is $1.97.

Cibus (NASDAQ:CBUS) last issued its earnings results on Thursday, May 14th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.06). Cibus had a negative net margin of 2,366.33% and a negative return on equity of 200.87%. The firm had revenue of $1.68 million during the quarter, compared to analyst estimates of $1.61 million. Equities analysts predict that Cibus, Inc. will post -1.05 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on CBUS shares. Wall Street Zen upgraded Cibus from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings downgraded Cibus from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cibus currently has an average rating of “Hold” and an average target price of $9.00.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.